Home LiteratureArticle Details
PMID: 10594474 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

British journal of clinical pharmacology ·Vol. 48 ·No. 5 ·1999-11-00 ·Pages 716-27

Kenworthy KE, Bloomer JC, Clarke SE, Houston JB

Abstract

Many substrates of cytochrome P450 (CYP) 3A4 are used for in vitro investigations of drug metabolism and potential drug-drug interactions. The aim of the present study was to determine the relationship between 10 commonly used CYP3A4 probes using modifiers with a range of inhibitory potency. The effects of 34 compounds on CYP3A4-mediated metabolism were investigated in a recombinant CYP3A4 expression system. Inhibition of erythromycin, dextromethorphan and diazepam N-demethylation, testosterone 6beta-hydroxylation, midazolam 1-hydroxylation, triazolam 4-hydroxylation, nifedipine oxidation, cyclosporin oxidation, terfenadine C-hydroxylation and N-dealkylation and benzyloxyresorufin O-dealkylation was evaluated at the apparent Km or S50 (for substrates showing sigmoidicity) value for each substrate and at an inhibitor concentration of 30 microM. While all CYP3A4 probe substrates demonstrate some degree of similarity, examination of the coefficients of determination, together with difference and cluster analysis highlighted that seven substrates can be categorized into two distinct substrate groups. Erythromycin, cyclosporin and testosterone form the most closely related group and dextromethorphan, diazepam, midazolam and triazolam form a second group. Terfenadine can be equally well placed in either group, while nifedipine shows a distinctly different relationship. Benzyloxyresorufin shows the weakest correlation with all the other CYP3A4 probes. Modifiers that caused negligible inhibition or potent inhibition are generally comparable in all assays, however, the greatest variability is apparent with compounds causing, on average, intermediate inhibition. Modifiers of this type may cause substantial inhibition, no effect or even activation depending on the substrate employed. It is recommended that multiple CYP3A4 probes, representing each substrate group, are used for the in vitro assessment of CYP3A4-mediated drug interactions.

MeSH Terms
Cytochrome P-450 CYP1A1/metabolism Cytochrome P-450 CYP3A Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Enzyme System/metabolism Enzyme Inhibitors/pharmacology Humans Kinetics Mixed Function Oxygenases/antagonists & inhibitors,metabolism Pharmaceutical Preparations/metabolism Recombinant Proteins/antagonists & inhibitors,metabolism
Chemicals
Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors Pharmaceutical Preparations Recombinant Proteins Cytochrome P-450 Enzyme System Mixed Function Oxygenases CYP3A protein, human Cytochrome P-450 CYP1A1 Cytochrome P-450 CYP3A CYP3A4 protein, human
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Kenworthy K E
School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK.
Bloomer J C
Clarke S E
Houston J B
References (35)
35 references, click to expand
  1. Identification of an inducible form of cytochrome P-450 in human liver.
    Proc Natl Acad Sci U S A. 1985 Sep;82(18):6310-4 PMID: 3898085
  2. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.
    Mol Pharmacol. 1989 Jul;36(1):89-96 PMID: 2787473
  3. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme.
    Arch Biochem Biophys. 1988 Jun;263(2):424-36 PMID: 3259858
  4. The erythromycin breath test as a predictor of cyclosporine blood levels.
    Clin Pharmacol Ther. 1990 Aug;48(2):120-9 PMID: 2116259
  5. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.
    Drug Metab Dispos. 1990 Sep-Oct;18(5):595-606 PMID: 1981707
  6. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol.
    Clin Pharmacol Ther. 1992 Jan;51(1):18-23 PMID: 1732074
  7. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity.
    Clin Pharmacol Ther. 1992 Sep;52(3):265-73 PMID: 1526083
  8. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients.
    Clin Pharmacol Ther. 1992 Nov;52(5):471-8 PMID: 1424421
  9. Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.
    Eur J Clin Pharmacol. 1993;44(2):163-9 PMID: 8453961
  10. The Cheng-Prusoff relationship: something lost in the translation.
    Trends Pharmacol Sci. 1993 Mar;14(3):89-91 PMID: 8488569
  11. Further concerns over Cheng-Prusoff analysis.
    Trends Pharmacol Sci. 1993 Apr;14(4):110-2 PMID: 8516953
  12. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation.
    Drug Metab Dispos. 1993 May-Jun;21(3):403-9 PMID: 8100494
  13. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men.
    Clin Pharmacol Ther. 1993 Dec;54(6):621-9 PMID: 8275617
  14. In vitro methods for assessing human hepatic drug metabolism: their use in drug development.
    Drug Metab Rev. 1993;25(4):453-84 PMID: 8313838
  15. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site.
    Biochemistry. 1994 May 31;33(21):6450-5 PMID: 8204577
  16. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
    Biochem Pharmacol. 1994 Jul 5;48(1):173-82 PMID: 8043020
  17. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms.
    Br J Clin Pharmacol. 1994 Aug;38(2):131-7 PMID: 7981013
  18. Noninvasive tests of CYP3A enzymes.
    Pharmacogenetics. 1994 Aug;4(4):171-84 PMID: 7987401
  19. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test.
    Clin Pharmacol Ther. 1994 Dec;56(6 Pt 1):608-14 PMID: 7995002
  20. The erythromycin breath test predicts the clearance of midazolam.
    Clin Pharmacol Ther. 1995 Jan;57(1):16-24 PMID: 7828377
  21. Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs.
    Biochem Pharmacol. 1995 Mar 1;49(5):591-602 PMID: 7887973
  22. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
    Drug Metab Dispos. 1994 Nov-Dec;22(6):947-55 PMID: 7895614
  23. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
    Drug Metab Dispos. 1995 Jan;23(1):154-8 PMID: 7720520
  24. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine.
    Clin Pharmacol Ther. 1995 Jul;58(1):15-9 PMID: 7628178
  25. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
    Drug Metab Dispos. 1995 Jul;23(7):765-75 PMID: 7587966
  26. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
    Clin Pharmacol Ther. 1996 Jan;59(1):47-51 PMID: 8549033
  27. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
    J Pharmacol Exp Ther. 1996 Apr;277(1):321-32 PMID: 8613937
  28. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.
    Anesth Analg. 1996 Mar;82(3):511-6 PMID: 8623953
  29. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
    J Pharmacol Exp Ther. 1996 Feb;276(2):370-9 PMID: 8632299
  30. Cooperativity in oxidations catalyzed by cytochrome P450 3A4.
    Biochemistry. 1997 Jan 14;36(2):370-81 PMID: 9003190
  31. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis.
    Drug Metab Dispos. 1997 Apr;25(4):502-7 PMID: 9107550
  32. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450.
    Anal Biochem. 1997 May 15;248(1):188-90 PMID: 9177742
  33. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
    Biochemistry. 1998 Mar 24;37(12):4137-47 PMID: 9521735
  34. In vitro and in vivo drug interactions involving human CYP3A.
    Annu Rev Pharmacol Toxicol. 1998;38:389-430 PMID: 9597161
  35. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.
    J Biol Chem. 1986 Apr 15;261(11):5051-60 PMID: 3514607
Article Info
Journal
British journal of clinical pharmacology
Abbr.
Br J Clin Pharmacol
ISSN
0306-5251
Published
1999-11-00
Pages
716-27
Language
English
Region
England
NLM ID
7503323
PMCID
PMC2014361
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com